Type I interferon suppresses virus-specific B cell responses by modulating CD8+ T cell differentiation

Science Immunology

Volumn 1, Issue 4, 2016, Pages

  Ashley Moseman, E ^a   Wu, Tuoqi ^b   de la Torre, Juan Carlos ^c   Schwartzberg, Pamela L ^b   McGavern, Dorian B ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84997122944     PISSN: None     EISSN: 24709468     Source Type: Journal    
DOI: 10.1126/sciimmunol.aah3565     Document Type: Article

References (72)

1. G. D. Victora, M. C. Nussenzweig, Germinal centers. Annu. Rev. Immunol. 30, 429–457 (2012).
2. S. L. Nutt, P. D. Hodgkin, D. M. Tarlinton, L. M. Corcoran, The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160–171 (2015).
3. D. Baumjohann, S. Preite, A. Reboldi, F. Ronchi, K. M. Ansel, A. Lanzavecchia, F. Sallusto, Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. Immunity 38, 596–605 (2013).
4. R. M. Welsh, L. K. Selin, E. Szomolanyi-Tsuda, Immunological memory to viral infections. Annu. Rev. Immunol. 22, 711–743 (2004).
5. H. W. Virgin, E. J. Wherry, R. Ahmed, Redefining chronic viral infection. Cell 138, 30–50 (2009).
6. + T cell-mediated protection against a lethal outcome of systemic infection with vesicular stomatitis virus requires CD40 ligand expression, but not IFN-g or IL-4. Int. Immunol. 11, 2035–2042 (1999).
7. K. H. Edelmann, C. B. Wilson, Role of CD28/CD80-86 and CD40/CD154 costimulatory interactions in host defense to primary herpes simplex virus infection. J. Virol. 75, 612–621 (2001).
8. M. B. Graham, T. J. Braciale, Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med. 186, 2063–2068 (1997).
9. J. K. Whitmire, M. K. Slifka, I. S. Grewal, R. A. Flavell, R. Ahmed, CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection. J. Virol. 70, 8375–8381 (1996).
10. B. Rehermann, C. Ferrari, C. Pasquinelli, F. V. Chisari, The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104–1108 (1996).
11. C. Logvinoff, M. E. Major, D. Oldach, S. Heyward, A. Talal, P. Balfe, S. M. Feinstone, H. Alter, C. M. Rice, J. A. McKeating, Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 101, 10149–10154 (2004).
12. H. Mouquet, Antibody B cell responses in HIV-1 infection. Trends Immunol. 35, 549–561 (2014).
13. L. Hangartner, R. M. Zinkernagel, H. Hengartner, Antiviral antibody responses: The two extremes of a wide spectrum. Nat. Rev. Immunol. 6, 231–243 (2006).
14. R. Ahmed, M. B. Oldstone, Organ-specific selection of viral variants during chronic infection. J. Exp. Med. 167, 1719–1724 (1988).
15. A. Bergthaler, L. Flatz, A. N. Hegazy, S. Johnson, E. Horvath, M. Löhning, D. D. Pinschewer, Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 107, 21641–21646 (2010).
16. B. M. Sullivan, S. F. Emonet, M. J. Welch, A. M. Lee, K. P. Campbell, J. C. de la Torre, M. B. Oldstone, Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Proc. Natl. Acad. Sci. U.S.A. 108, 2969–2974 (2011).
17. M. B. A. Oldstone, Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr. Top. Microbiol. Immunol. 263, 83–117 (2002).
18. M. K. Slifka, Mechanisms of humoral immunity explored through studies of LCMV infection. Curr. Top. Microbiol. Immunol. 263, 67–81 (2002).
19. B. Oliviero, A. Cerino, S. Varchetta, E. Paudice, S. Pai, S. Ludovisi, M. Zaramella, G. Michelone, P. Pugnale, F. Negro, V. Barnaba, M. U. Mondelli, Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J. Hepatol. 55, 53–60 (2011).
20. S. Moir, A. S. Fauci, B cells in HIV infection and disease. Nat. Rev. Immunol. 9, 235–245 (2009).
21. J. E. Roughan, K. M. Reardon, K. E. Cogburn, H. Quendler, P. J. Pockros, M. Law, Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Clin. Vaccine Immunol. 19, 1027–1037 (2012).
22. L. Hangartner, R. M. Zellweger, M. Giobbi, J. Weber, B. Eschli, K. D. Mccoy, N. Harris, M. Recher, R. M. Zinkernagel, H. Hengartner, Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. J. Exp. Med. 203, 2033–2042 (2006).
23. A. Bergthaler, L. Flatz, A. Verschoor, A. N. Hegazy, M. Holdener, K. Fink, B. Eschli, D. Merkler, R. Sommerstein, E. Horvath, M. Fernandez, A. Fitsche, B. M. Senn, J. S. Verbeek, B. Odermatt, C.-A. Siegrist, D. D. Pinschewer, Impaired antibody response causes persistence of prototypic T cell-contained virus. PLOS Biol. 7, e1000080 (2009).
24. D. Masopust, K. Murali-Krishna, R. Ahmed, Quantitating the magnitude of the lymphocytic choriomeningitis virus-specific CD8 T-cell response: It is even bigger than we thought. J. Virol. 81, 2002–2011 (2007).
25. D. S. McDermott, S. M. Varga, Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think. J. Immunol. 187, 5568–5576 (2011).
26. S. N. Mueller, M. Matloubian, D. M. Clemens, A. H. Sharpe, G. J. Freeman, S. Gangappa, C. P. Larsen, R. Ahmed, Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection. Proc. Natl. Acad. Sci. U.S.A. 104, 15430–15435 (2007).
27. S. N. Mueller, K. A. Hosiawa-Meagher, B. T. Konieczny, B. M. Sullivan, M. F. Bachmann, R. M. Locksley, R. Ahmed, M. Matloubian, Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 317, 670–674 (2007).
28. M. Recher, K. S. Lang, L. Hunziker, S. Freigang, B. Eschli, N. L. Harris, A. Navarini, B. M. Senn, K. Fink, M. Lötscher, L. Hangartner, R. Zellweger, M. Hersberger, A. Theocharides, H. Hengartner, R. M. Zinkernagel, Deliberate removal of T cell help improves virus-neutralizing antibody production. Nat. Immunol. 5, 934–942 (2004).
29. D. D. Pinschewer, M. Perez, E. Jeetendra, T. Bächi, E. Horvath, H. Hengartner, M. A. Whitt, J. C. de la Torre, R. M. Zinkernagel, Kinetics of protective antibodies are determined by the viral surface antigen. J. Clin. Invest. 114, 988–993 (2004).
30. O. Planz, P. Seiler, H. Hengartner, R. M. Zinkernagel, Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected]. Nature 382, 726–729 (1996).
31. B. Eschli, R. M. Zellweger, A. Wepf, K. S. Lang, K. Quirin, J. Weber, R. M. Zinkernagel, H. Hengartner, Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus. J. Virol. 81, 11650–11657 (2007).
32. L. Hangartner, B. M. Senn, B. Ledermann, U. Kalinke, P. Seiler, E. Bucher, R. M. Zellweger, K. Fink, B. Odermatt, K. Bürki, R. M. Zinkernagel, H. Hengartner, Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 100, 12883–12888 (2003).
33. I. Osokine, L. M. Snell, C. R. Cunningham, D. H. Yamada, E. B. Wilson, H. J. Elsaesser, J. C. de la Torre, D. Brooks, Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proc. Natl. Acad. Sci. U.S.A. 111, 7409–7414 (2014).
34. R. M. Zellweger, L. Hangartner, J. Weber, R. M. Zinkernagel, H. Hengartner, Parameters governing exhaustion of rare T cell-independent neutralizing IgM-producing B cells after LCMV infection. Eur. J. Immunol. 36, 3175–3185 (2006).
35. J. R. Teijaro, C. Ng, A. M. Lee, B. M. Sullivan, K. C. F. Sheehan, M. Welch, R. D. Schreiber, J. C. de la Torre, M. B. A. Oldstone, Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207–211 (2013).
36. C. R. Bolen, M. D. Robek, L. Brodsky, V. Schulz, J. K. Lim, M. W. Taylor, S. H. Kleinstein, The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response. J. Interferon Cytokine Res. 33, 15–23 (2013).
37. T. Doyle, C. Goujon, M. H. Malim, HIV-1 and interferons: Who’s interfering with whom? Nat. Rev. Microbiol. 13, 403–413 (2015).
38. E. B. Wilson, D. H. Yamada, H. Elsaesser, J. Herskovitz, J. Deng, G. Cheng, B. J. Aronow, C. L. Karp, D. G. Brooks, Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202–207 (2013).
39. C. T. Ng, B. M. Sullivan, J. R. Teijaro, A. M. Lee, M. Welch, S. Rice, K. C. F. Sheehan, R. D. Schreiber, M. B. A. Oldstone, Blockade of interferon beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 17, 653–661 (2015).
40. K. Fink, K. S. Lang, N. Manjarrez-Orduno, T. Junt, B. M. Senn, M. Holdener, S. Akira, R. M. Zinkernagel, H. Hengartner, Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur. J. Immunol. 36, 2094–2105 (2006).
41. T. Junt, E. A. Moseman, M. Iannacone, S. Massberg, P. A. Lang, M. Boes, K. Fink, S. E. Henrickson, D. M. Shayakhmetov, N. C. Di Paolo, N. van Rooijen, T. R. Mempel, S. P. Whelan, U. H. von Andrian, Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature 450, 110–114 (2007).
42. P. Seiler, P. Aichele, B. Odermatt, H. Hengartner, R. M. Zinkernagel, R. A. Schwendener, Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 27, 2626–2633 (1997).
43. S. Müller, L. Hunziker, S. Enzler, M. Bühler-Jungo, J. P. Di Santo, R. M. Zinkernagel, C. Mueller, Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production. J. Virol. 76, 2375–2383 (2002).
44. L. M. Fahey, E. B. Wilson, H. Elsaesser, C. D. Fistonich, D. B. McGavern, D. G. Brooks, Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208, 987–999 (2011).
45. K. A. Hogquist, S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, F. R. Carbone, T cell receptor antagonist peptides induce positive selection. Cell 76, 17–27 (1994).
46. J. M. Curtsinger, M. F. Mescher, Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22, 333–340 (2010).
47. H. Pircher, K. Bürki, R. Lang, H. Hengartner, R. M. Zinkernagel, Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342, 559–561 (1989).
48. T.-W. Chen, T. J. Wardill, Y. Sun, S. R. Pulver, S. L. Renninger, A. Baohan, E. R. Schreiter, R. A. Kerr, M. B. Orger, V. Jayaraman, L. L. Looger, K. Svoboda, D. S. Kim, Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature 499, 295–300 (2013).
49. D. R. Shimshek, J. Kim, M. R. Hübner, D. J. Spergel, F. Buchholz, E. Casanova, A. F. Stewart, P. H. Seeburg, R. Sprengel, Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis 32, 19–26 (2002).
50. H. J. Snippert, L. G. van der Flier, T. Sato, J. H. van Es, M. van den Born, C. Kroon-Veenboer, N. Barker, A. M. Klein, J. van Rheenen, B. D. Simons, H. Clevers, Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 143, 134–144 (2010).
51. T. P. Leist, E. Rüedi, R. M. Zinkernagel, Virus-triggered immune suppression in mice caused by virus-specific cytotoxic T cells. J. Exp. Med. 167, 1749–1754 (1988).
52. O. Planz, P. Seiler, H. Hengartner, R. M. Zinkernagel, Specific cytotoxic T cells eliminate cells producing neutralizing antibodies. Nature 426, 474 (2003).
53. X. Wu, T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N. S. Longo, M. Louder, K. McKee, S. O’Dell, S. Perfetto, S. D. Schmidt, W. Shi, L. Wu, Y. Yang, Z.-Y. Yang, Z. Yang, Z. Zhang, M. Bonsignori, J. A. Crump, S. H. Kapiga, N. E. Sam, B. F. Haynes, M. Simek, D. R. Burton, W. C. Koff, N. A. Doria-Rose, M. Connors; NISC Comparative Sequencing Program, J. C. Mullikin, G. J. Nabel, M. Roederer, L. Shapiro, P. D. Kwong, J. R. Mascola, Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593–1602 (2011).
54. N. C. Robson, A. M. Donachie, A. M. Mowat, Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells. Eur. J. Immunol. 38, 1238–1246 (2008).
55. + T cells. Immunol. Rev. 211, 81–92 (2006).
56. + T-cell response in vivo. Blood 109, 1086–1094 (2007).
57. D. Paus, T. G. Phan, T. D. Chan, S. Gardam, A. Basten, R. Brink, Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J. Exp. Med. 203, 1081–1091 (2006).
58. K. Fink, N. Manjarrez-Orduño, A. Schildknecht, J. Weber, B. M. Senn, R. M. Zinkernagel, H. Hengartner, B cell activation state-governed formation of germinal centers following viral infection. J. Immunol. 179, 5877–5885 (2007).
59. E. J. Kunkel, E. C. Butcher, Plasma-cell homing. Nat. Rev. Immunol. 3, 822–829 (2003).
60. A. E. Hauser, G. F. Debes, S. Arce, G. Cassese, A. Hamann, A. Radbruch, R. A. Manz, Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J. Immunol. 169, 1277–1282 (2002).
61. J. H. Sung, H. Zhang, E. A. Moseman, D. Alvarez, M. Iannacone, S. E. Henrickson, J. C. de la Torre, J. R. Groom, A. D. Luster, U. H. von Andrian, Chemokine guidance of central memory T cells is critical for antiviral recall responses in lymph nodes. Cell 150, 1249–1263 (2012).
62. D. H. Yamada, H. Elsaesser, A. Lux, J. M. Timmerman, S. L. Morrison, J. C. de la Torre, F. Nimmerjahn, D. G. Brooks, Suppression of Fcg-receptor-mediated antibody effector function during persistent viral infection. Immunity 42, 379–390 (2015).
63. S. F. Emonet, L. Garidou, D. B. McGavern, J. C. de la Torre, Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl. Acad. Sci. U.S.A. 106, 3473–3478 (2009).
64. M. Battegay, S. Cooper, A. Althage, J. Bänziger, H. Hengartner, R. M. Zinkernagel, Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods 33, 191–198 (1991).
65. B. H. Zinselmeyer, S. Heydari, C. Sacristán, D. Nayak, M. Cammer, J. Herz, X. Cheng, S. J. Davis, M. L. Dustin, D. B. McGavern, PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 210, 757–774 (2013).
66. M. D. Muzumdar, B. Tasic, K. Miyamichi, L. Li, L. Luo, A global double-fluorescent Cre reporter mouse. Genesis 45, 593–605 (2007).
67. D. Kägi, B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, H. Hengartner, Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31–37 (1994).
68. D. R. Fooksman, T. A. Schwickert, G. D. Victora, M. L. Dustin, M. C. Nussenzweig, D. Skokos, Development and migration of plasma cells in the mouse lymph node. Immunity 33, 118–127 (2010).
69. S. Gossa, D. Nayak, B. H. Zinselmeyer, D. B. McGavern, Development of an immunologically tolerated combination of fluorescent proteins for in vivo two-photon imaging. Sci. Rep. 4, 6664 (2014).
70. U. Muller, U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, M. Aguet, Functional role of type I and type II interferons in antiviral defense. Science 264, 1918–1921 (1994).
71. A. Oxenius, M. F. Bachmann, R. M. Zinkernagel, H. Hengartner, Virus-specific MHC-class II-restricted TCR-transgenic mice: Effects on humoral and cellular immune responses after viral infection. Eur. J. Immunol. 28, 390–400 (1998).
72. E. E. Devlin, L. Dacosta, N. Mohandas, G. Elliott, D. M. Bodine, A transgenic mouse model demonstrates a dominant negative effect of a point mutation in the RPS19 gene associated with Diamond-Blackfan anemia. Blood 116, 2826–2835 (2010).